Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 801–900 of 1,001
Models in Pancreatic Neuroendocrine Neoplasms: Current Perspectives and Future Directions
Forsythe, S. D., Pu, T., Andrews, S. G., Madigan, J. P., & Sadowski, S. M. (2023) · Cancers · doi:10.3390/cancers15153756 · Cited by 24
Tumor organoid model of colorectal cancer (Review)
Yang, C., Xiao, W., Wang, R., Hu, Y., Yi, K., Sun, X., Wang, G., & Xu, X. (2023) · Oncology Letters · doi:10.3892/ol.2023.13914 · Cited by 27
“Molecular profiling of organoids is matched with the results of drug screening, which may predict the clinical response of patients to various medications (90).”
MethodResultBreast cancer organoids and their applications for precision cancer immunotherapy
Guan, D., Liu, X., Shi, Q., He, B., Zheng, C., & Meng, X. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03231-2 · Cited by 23
Leto, S. M., Grassi, E., Avolio, M., Vurchio, V., Cottino, F., Ferri, M., Zanella, E. R., Borgato, S., Corti, G., di Blasio, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51909-2 · Cited by 24
“The selected antibody concentration was based on existing literature data and represented an intermediate dose reported to achieve an inhibi-toryplateauacrossCRCcelllinesandtumoroids 9,17,36,42,43 .”
Madan, A., Saini, R., Dhiman, N., Juan, S., & Satapathy, M. K. (2025) · Organoids · doi:10.3390/organoids4040023 · Cited by 24
“The study reported a sensitivity of 88% and specificity of 100% for predicting clinical response, establishing PDOs as powerful functional correlates of therapeutic efficacy in CRC [96].”
New developments and applications of human organoids
Andersson-Rolf, A., & Clevers, H. C. (2026) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-026-00974-0 · Cited by 39
Tung, K., Chen, K., Negrete, M., Chen, T., Safi, A., Aljamal, A. A., Song, L., Crawford, G. E., Ding, S., Hsu, D. S., et al. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.10.012 · Cited by 23
Dominijanni, A. J., Mazzocchi, A. R., Shelkey, E., Forsythe, S. D., Devarasetty, M., & Söker, S. (2020) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2020.03.005 · Cited by 20
“Studies are usually aimed at testing large panels of approved and experimental compounds on previously genotyped patients in an attempt to discover novel treatment options [1].”
BackgroundMultimodal predictors for precision immunotherapy
Roelofsen, L. M., Kaptein, P., & Thommen, D. S. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100071 · Cited by 20
DeStefanis, R. A., Kratz, J. D., Olson, A. M., Sunil, A., DeZeeuw, A. K., Gillette, A. A., Sha, G. C., Johnson, K. A., Pasch, C. A., Clipson, L. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-08937-z · Cited by 22
Recent advances and challenges in organoid-on-a-chip technology
Suhito, I. R., & Kim, T. P. (2022) · Organoid · doi:10.51335/organoid.2022.2.e4 · Cited by 21
Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer
Iyer, K. K., van Erp, N. P., Tauriello, D. V. F., Verheul, H. M. W., & Poel, D. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102466 · Cited by 20
Smolková, B., Kataki, A., Earl, J., Ruz‐Caracuel, I., Cihova, M., Urbanova, M., Buociková, V., Tamargo, S., Rovīte, V., Niedra, H., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103865 · Cited by 21
The tumor microenvironment and immune targeting therapy in pediatric renal tumors
Hont, A. B., Dumont, B., Sutton, K. S., Anderson, J., Kentsis, A., Drost, J., Hong, A. L., & Verschuur, A. C. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.30110 · Cited by 19
Advancements in melanoma cancer metastasis models
Melo, L. M. N., Kumar, S., Riess, V., Szylo, K. J., Eisenburger, R. T., Schadendorf, D., Ubellacker, J. M., & Tasdogan, A. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13078 · Cited by 24
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity
Liu, H., Su, H., Wang, F., Dang, Y., Ren, Y., Yin, S., Lu, H., Zhang, H., Wu, J., Xu, Z., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112275 · Cited by 21
Cao, R., Li, N. T., Latour, S., Cadavid, J. L., Tan, C. M., Forman, A., Jackson, H. W., & McGuigan, A. P. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202422 · Cited by 25
Divoux, J., Florent, R., Jacobs, M., Lequesne, J., Grellard, J., San, C., Grossi, S. M., Kerdja, K., Clarisse, B., Boudier, G., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11362-8 · Cited by 24
“PDTO have thus been shown to be able to predict the response to chemotherapy of gastrointestinal [14] and pancreatic tumors [15] as well as the sensitivity of colorectal cancers to radiotherapy [16].”
BackgroundModels for evaluating glioblastoma invasion along white matter tracts
Li, Y. O., Wang, J., Song, S.-R., Lv, S., Qin, J., & Yu, S. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.09.005 · Cited by 25
Engineering Heterogeneous Tumor Models for Biomedical Applications
Wu, Z., Huang, D., Wang, J., Zhao, Y., Sun, W., & Shen, X. (2023) · Advanced Science · doi:10.1002/advs.202304160 · Cited by 25
Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research
Waseem, M., & Wang, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021093 · Cited by 23
“PCa organoids have been suggested as promising in vitro or ex vivo models to study the drug efficacies/responses, and the results can serve as good references for predicting clinical outcomes [14,26,36,161,162].”
BackgroundGao, C., Jiang, J., Zhao, J., Xu, Z. P., & Zhang, L. L. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216109 · Cited by 25
Signals and forces shaping organogenesis of the small intestine
Wang, S., Walton, K. D., & Gumucio, D. L. (2019) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2018.12.001 · Cited by 22
“…et al., 2014; Hill et al., 2017), examining the role of specific cell types in intestinal morphogenesis (Schlieve et al., 2017; Workman et al., 2017), drug screening (Baumann, 2017; Liu et al., 2016), and studying patient specific diseases (VanDussen et al., 2015; Vlachogiannis et al., 2018).”
The potential application of organoids in breast cancer research and treatment
Ebrahimi, N., Esfahani, A. N., Samizade, S., Mansouri, A., Ghanaatian, M., Adelian, S., Shadman-Manesh, V., & Hamblin, M. R. (2021) · Human Genetics · doi:10.1007/s00439-021-02390-0 · Cited by 22
In vitro drug testing using patient-derived ovarian cancer organoids
Chen, L., Chou, Y.-T., Liew, P., Chu, L.-H., Wen, K., Lin, S., Weng, Y., Wang, H.-C., Su, P., & Lai, H. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01520-2 · Cited by 27
Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications
Paul, C. D., Yankaskas, C., Thakuri, P. S., Balhouse, B. N., Salen, S., Bullock, A., Beam, S., Chatman, A., Djikeng, S., Yang, X. J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-86979-9 · Cited by 20
Hepatic organoids as a platform for liver disease modeling and the development of novel therapies
Luce, E., Messina, A., & Duclos‐Vallée, J. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102647 · Cited by 24
Zhou, Y., Yu, F., Guo, M., Tang, Y., & Xu, Q. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1498141 · Cited by 26
Phenotype transition of fibroblasts incorporated into patient‐derived oral carcinoma organoids
Chen, X., Li, R., Zhao, H., Wang, X., Shao, Z., & Shang, Z. (2021) · Oral Diseases · doi:10.1111/odi.14071 · Cited by 22
Babaei‐Jadidi, R., Kashfi, H., Alelwani, W., Bakhtiari, A. K., Kattan, S. W., Mansouri, O. A., Mukherjee, A., Lobo, D. N., & Nateri, A. S. (2022) · Oncogenesis · doi:10.1038/s41389-021-00376-1 · Cited by 21
USP7 inactivation suppresses APC-mutant intestinal hyperproliferation and tumor development
Novellasdemunt, L., Kucharska, A., Baulies, A., Hutton, C., Vlachogiannis, G., Repana, D., Rowan, A., Suárez‐Bonnet, A., Ciccarelli, F. D., Valeri, N., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.12.013 · Cited by 20
Self-citationTamoxifen induces ferroptosis in MCF-7 organoid
Ye, L., Zhong, F., Sun, S., Ou, X., Yuan, J., Zhu, J., & Zeng, Z. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_608_23 · Cited by 22
Establishing mouse and human oral esophageal organoids to investigate the tumor immune response
Jiang, Y., Zhao, H., Kong, S., Zhou, D., Dong, J., Cheng, Y., Zhang, S., Wang, F., Kalra, A., Yang, N., et al. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050319 · Cited by 20
“…other common cancer types, including colon cancer (Pauli et al., 2017; van de Wetering et al., 2015), gastrointestinal cancers (Sato et al., 2011; Vlachogiannis et al., 2018), pancreatic cancer (Boj et al., 2015; Broutier et al., 2016), breast cancer (Dekkers et al., 2021; Sachs et al., 2018)…”
Organoid models: the future companions of personalized drug development
Piraino, F., Costa, M., Meyer, M., Cornish, G. H., Ceroni, C., Garnier, V., Hoehnel, S., & Brandenberg, N. (2024) · Biofabrication · doi:10.1088/1758-5090/ad3e30 · Cited by 24
“This enabled the comparison of clinical responses with organoid drug responses, show-casing the value of PDTOs in drug screening [86].”
Matrix-free human lung organoids derived from induced pluripotent stem cells to model lung injury
Budeus, B., Kroepel, C., Stasch, L. M., & Klein, D. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04106-3 · Cited by 27
“For example, it has already been shown that drug response in patients could be matched to that of organoid cultures by up to 90% [5].”
Valeri, N. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0305 · Cited by 19
“From this perspective, refining the selection criteria for testing kinase gene fusions might translate into amore accurate selection of patients for molecular screening, thus enabling biobanking efforts of patient-based models such as organoids (10) mimicking uncommon genetic drivers.”
BackgroundSelf-citationSomarelli, J. A., Rupprecht, G., Altunel, E., Flamant, E. M., Rao, S. R., Sivaraj, D., Lazarides, A. L., Hoskinson, S. M., Sheth, M. U., Cheng, S., et al. (2020) · Cancers · doi:10.3390/cancers12113335 · Cited by 19
“Patient-derived models of cancer, includi l - e cell lines [15], patient-derived organoids [16,17], and patient-derived xenografts ( s) [18], are increasingly being used as “standard” preclinical models to identify sensitivities to ne candidate therapeutics across cancers.”
BackgroundSelf-citationPotent pro-apoptotic combination therapy is highly effective in a broad range of cancers
Montinaro, A., Zubiaur, I. A., Saggau, J., Kretz, A.-L., Ferreira, R. M. M., Hassan, O., Kitzig, E. F., Müller, I., El-Bahrawy, M. A., von Karstedt, S., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00869-x · Cited by 23
What gastroenterologists and hepatologists should know about organoids in 2019
Günther, C., Brevini, T., Sampaziotis, F., & Neurath, M. F. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.02.020 · Cited by 22
“[52] Vlachogiannis G, Hedayat S, Vatsiou A, et al.”
BackgroundBoghaert, E. R., Cox, M. C., & Vaidya, K. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3236 · Cited by 17
Harnessing Organoid Platforms for Nanoparticle Drug Development
Chen, L., Luo, X., Zhang, J., Zhang, J., Yang, C., & Zhao, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s530999 · Cited by 21
“100 The clinical predictive power of CRC organoids is particularly evident in therapeutic response modeling.”
Yin, L., Zhou, S., Zhang, H., Shang, Y., Wu, S., & Jin, T. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1619597 · Cited by 22
“The establishment of PDO biobanks, large-scale collections of organoids from diverse patients, could enable high-throughput drug screening (HTS), which facilitate the identification of novel therapeutics and personalized treatment strategies (Vlachogiannis et al., 2018).”
Bieńkowski, M., Tomasik, B., Braun, M., & Jassem, J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102359 · Cited by 20
A brief history of testicular organoids: from theory to the wards
Wang, N., Jiaming, S., Minghua, L. I. U., Ma, L., Lina, Q. I. N., Xuemei, G. E., & Hongli, Y. A. N. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02529-6 · Cited by 17
“The results obtained by Valeri [19] demonstrated that the molecular profiling of tumor organoids was matched to drug screening results, suggesting that patient-derived organoids (PDOs) could complement existing approaches in defining cancer vulnerabilities and improving treatment responses.”
BackgroundResultSattar, R. S. A., Verma, R., Nimisha, Kumar, A., Dar, G. M., Apurva, A., Sharma, A. K., Kumari, I., Ahmad, E., Ali, A., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110413 · Cited by 19
Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery
Kim, Y. S., Hsieh, A. C., & Lam, H. (2022) · European Urology Focus · doi:10.1016/j.euf.2022.07.006 · Cited by 17
Engineering the Immune Microenvironment into Organoid Models
Luckett, K. A., & Ganesh, K. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-040659 · Cited by 23
Reconstruction of tumor microenvironment via in vitro three-dimensional models
Zhou, Z., He, J., Pang, Y., & Sun, W. Y. (2023) · Biofabrication · doi:10.1088/1758-5090/acd1b8 · Cited by 18
“Patient-derived organoids (PDOs) have been proven to robustly predict clinical patient responses to drugs in various cancers, such as colorectal, rectal, and gastrointestinal cancers [57, 59, 60].”
In-vitro model to mimic T cell subset change in human PDAC organoid co-culture
Knoblauch, M., Ma, T., Beirith, I., Koch, D. T., Hofmann, F. O., Heinrich, K., Aghamaliev, U., Sirtl, S., Westphalen, C. B., Nieß, H., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05100-7 · Cited by 28
“Up to now, organoid models have been favourably established for several cancer entities (Broutier et al. 2017; Sachs et al. 2018; Seino et al. 2018; Vlachogiannis et al. 2018; Weeber et al. 2015).”
BackgroundAddressing Key Questions in Organoid Models: Who, Where, How, and Why?
Gómez‐Álvarez, M., Agustina‐Hernández, M., Francés‐Herrero, E., Rodríguez‐Eguren, A., Bueno-Fernández, C., & Cervelló, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242116014 · Cited by 20
“Notably, pancreatic [149], colorectal [148], and brain [150] cancer organoids represent a small subset of the numerous cancer organoids documented to date.”
BackgroundKim, D., Park, J., Park, H., Zhang, S., Park, M., Park, S. A., Lee, S. H., Lee, Y. S., Park, J., Jeun, S., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03225-4 · Cited by 21
“Several tumor organoids have been established from diverse types of cancer including breast [15], lung [16], liver [17], pancreatic [18], and gastrointestinal cancers [19].”
BackgroundThng, D. K. H., Hooi, L., Siew, B. E., Lee, K.-Y., Tan, I. J.-W., Lieske, B., Lin, N. S., Kow, A. W. C., Wang, S., Rashid, M. B. M. A., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00543-8 · Cited by 21
“Noticeably, with the protocol for the generation of patient-derived avatars of different cancers, including CRC, being established, there is a growing number of preclinical studies demonstrating the correlative concordance betweenex vivo and clinical responsesoftumours to the same therapies 24,25 .”
BackgroundInfluentialHu, H., Sun, C., Chen, J., & Li, Z. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05654-0 · Cited by 21
“…histochemical phenotype of tumors, and maintain gene stability and disease-state phenotype during long-term passage, offering the benefit of a shorter modeling time and higher fidelity to the primary tumor in comparison to conventional models (Dijkstra et al. 2018; Vlachogiannis et al. 2018).”
BackgroundNovel three-dimensional cultures provide insights into thyroid cancer behavior
Lee, M. A., Bergdorf, K. N., Phifer, C. J., Jones, C. Y., Byon, S. Y., Sawyer, L. M., Bauer, J. A., & Weiss, V. L. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0374 · Cited by 20
Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic
Ney, A., Canciani, G., Hsuan, J. J., & Pereira, S. P. (2020) · Cancers · doi:10.3390/cancers12113170 · Cited by 20
“Organoids have been developed from gastrointestinal cancers arising in various tissues [80], including PDAC, with 75–85% success rates [81].”
Backgroundvan Dooremalen, W. T. M., Derksen, M., Roos, J. L., Barón, C. H., Veríssimo, C. S., Vries, R. G. J., Boj, S. F., & Pourfarzad, F. (2021) · Journal of Visualized Experiments · doi:10.3791/62074 · Cited by 23
Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold
Hu, L., Yang, X. F., Lan, H., Fang, X., Chen, X., & Jin, K. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112858 · Cited by 22
Ye, H., Gao, H., Li, H., Nie, J., Li, T., Lu, M., Wu, M., Liu, J., & Wang, K. (2022) · Phytotherapy Research · doi:10.1002/ptr.7515 · Cited by 23
“It has been reported that the positive predictive value of PDO-based drug screening is 88% and the negative predictive value is 100% in forecasting the response to targeted agents or chemotherapy in vivo (Vlachogiannis et al., 2018).”
BackgroundTargeting POLE2 Creates a Novel Vulnerability in Renal Cell Carcinoma via Modulating Stanniocalcin 1
Zhang, C., Shen, Y., Gao, L., Wang, X., Huang, D., Xie, X., Xu, D., & He, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.622344 · Cited by 18
Mouse Models of Metastasis and Dormancy
Mahmoud, A., & Ganesh, K. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041386 · Cited by 20
Tan, T., Mouradov, D., Gibbs, P., & Sieber, O. M. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103090 · Cited by 20
Deligne, C., Tourbez, A., Bénard, F., Meyer, S., Curt, A., Gianesello, M., Hamadou, M., Clavier, L., Coquet, C., Bocquet, C., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf007 · Cited by 20
Soft 3D Bioelectrodes for Intraorganoid Signal Monitoring in Cardiac Models
Park, Y., Kim, S., Min, S., Kim, E., Kim, D., Cho, Y. H., Kim, S., Joo, H., Jeong, I., Lim, J. A., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c00069 · Cited by 18
Bozym, D. J., Zheng, D. X., Revach, O., Aref, A. R., & Jenkins, R. W. (2025) · Lab on a Chip · doi:10.1039/d5lc00062a · Cited by 21
Bioprinted Organoids: An Innovative Engine in Biomedicine
Li, Z., Li, K., Zhang, C., Zhao, Y., Guo, Y., He, J., Chang, S., Fang, X., Liu, K., Zhu, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202507317 · Cited by 34
Zhang, Y., Yu, R., Li, Q., Song, S., Fu, Y. S., Shen, X., Xu, T., Zhang, Y., Liang, J., Zhang, Z., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013269 · Cited by 20
Organoid research: new concepts and new technologies
Zhang, J., Wu, Y., Shen, T., Mao, Y., Dou, H., Lin, Y., Geng, Z., Li, Z., & Su, J. (2026) · Burns & Trauma · doi:10.1093/burnst/tkag015 · Cited by 26
“Vlachogiannis et al . collected 110 fresh tissue samples from 71 patients and established an organoid biobank derived from metastatic, posttreatment colorectal cancer, and gastroesophageal cancer samples using a 3D culture system [92].”
Chang, T. C., Matossian, M. D., Elliott, S. G., Burks, H. E., Sabol, R. A., Uçar, D. A., Wathieu, H., Zabaleta, J., Valle, L. D., Gill, S. K., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226464 · Cited by 18
“Furthermore, organoids have been shown to more accurately predict clinical response to therapeutics, compared to cell line studies [57, 58].”
ResultThe Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
Low, R. R. J., Lim, W., Nguyen, P. M., Lee, B., Christie, M., Burgess, A. W., Gibbs, P., Grimmond, S. M., Hollande, F., & Putoczki, T. L. (2021) · Cancers · doi:10.3390/cancers13194979 · Cited by 20
Organoids as research models for hepatocellular carcinoma
Yu, J. H., & Ma, S. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112987 · Cited by 17
Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy
Zitter, R., Chugh, R. M., & Saha, S. (2022) · Cancers · doi:10.3390/cancers14123006 · Cited by 20
“The first is the maintained degree of genetic similarity to the original biopsy [37].”
BackgroundDou, Y., Pizarro, T. T., & Zhou, L. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.06.008 · Cited by 17
“Similar observations in metastatic gastrointestinal cancers were reported by Vlachogiannis et al.80 They showed that genomic, transcriptional, and morphologic profiling of patient-derived CRC organoids largely overlaps with those from patient biopsies.80 These findings strongly support feasibility of exploiting the or…”
ResultInfluentialFrom simplicity to complexity in current melanoma models
Michielon, E., de Gruijl, T. D., & Gibbs, S. (2022) · Experimental Dermatology · doi:10.1111/exd.14675 · Cited by 19
From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer
Betge, J., & Jackstadt, R. (2022) · International Journal of Cancer · doi:10.1002/ijc.34297 · Cited by 19
“Vlachogiannis et al(68) compared the response of selected gastrointestinal cancer patients with matched organoids, when treated with the same substances.(68) They established organoid cultures from tumors of heavily pretreated patients”
BackgroundShie, M., Fang, H., Kan, K., Ho, C., Tu, C., Lee, P., Hsueh, P., Chen, C., Lee, A. K.-X., Tien, N., et al. (2023) · Advanced Science · doi:10.1002/advs.202206603 · Cited by 20
Alipourgivi, F., Motolani, A., Qiu, A.-H., Qiang, W., Yang, G., Chen, S., & Lu, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010154 · Cited by 17
“Such “living biobanks” would offer not only unique insights into broad cancer phenotypes but also a platform for high-throughput drug screens, thus, facilitating a better understanding of CRC as well as the development of patient-specific treatment regimens [53,56,57] (Figure 5).”
BackgroundFang, X.-C., Shu, L., Chen, T., Zhao, X., Yang, L., Dou, T., Yang, L., Li, X., & Feng, M. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01901-z · Cited by 20
“Patient-derived organoid compounds (PDO) have been successfully applied to the study of multiple tumors, including breast [34], colorectal [35], stomach [36], gastrointestinal [37], prostate [38], lung [39], liver [40], pancreas [41], and nasopharyngeal [42].”
BackgroundKüstermann, C., Narbute, K., Movčana, V., Parfejevs, V., Rūmnieks, F., Kauķis, P., Priedols, M., Mikilps-Mikgelbs, R., Mihailova, M., Andersone, S., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03862-6 · Cited by 20
“Studies have shown that patient-derived organoids can faithfully recapitulate patient responses to chemotherapy and are instrumental in guiding personalized treatment decisions [19, 34].”
BackgroundAdvances in the application of colorectal cancer organoids in precision medicine
Zhang, Y., Meng, R., Sha, D., Gao, H., Wang, S., Zhou, J., Wang, X., Li, F., Li, X., & Song, W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1506606 · Cited by 19
Preclinical Modelling of PDA: Is Organoid the New Black?
D’Agosto, S. L., Andreani, S., Scarpa, A., & Corbo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112766 · Cited by 17
“Cross-referencing PDOs to patients’ responses, the authors showed the high predictive value of organoids-based drug testing [71].”
BackgroundMethodInfluentialOrganotypic Modeling of the Tumor Landscape
Haykal, M. M., Nahmias, C., Varon, C., & Martin, O. C. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606039 · Cited by 19
“Even if the use of functional testing in guiding personalized medicine in still in its infancy, the use of metastatic cancer site derived PDOs to evaluate drug response has proven its efficacy by recapitulating patient response (Weeber et al., 2015; Fujii et al., 2016; Pauli et al., 2017; Vlachogiannis et al., 2018).”
BackgroundPatient-Derived Organoids in Precision Oncology – Towards a Science of and for the Individual?
Green, S., Dam, M. S., & Svendsen, M. N. (2022) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-74804-3_7 · Cited by 17
Organoid Models for Cancer Research—From Bed to Bench Side and Back
Kastner, C., Hendricks, A., Deinlein, H., Hankir, M. K., Germer, C., Schmidt, S., & Wiegering, A. (2021) · Cancers · doi:10.3390/cancers13194812 · Cited by 18
Ishida, A., Shichi, H., Fukuoka, H., Inoshita, N., Ogawa, W., & Yamada, S. (2021) · Pituitary · doi:10.1007/s11102-021-01192-x · Cited by 19
Efficacy of molecular and nano-therapies on brain tumor models in microfluidic devices
Martins, A. M., Brito, A., Barbato, M. G., Felici, A., Reis, R. L., Pires, R. A., Pashkuleva, I., & Decuzzi, P. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213227 · Cited by 17
Cancer-on-a-chip for Drug Screening
Lee, I. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206235233 · Cited by 17
Shuford, R. A., Cairns, A., & Moaven, O. (2020) · Cancers · doi:10.3390/cancers12113481 · Cited by 18
“These models have been shown to be a feasible pipeline for drug screening, predicting treatment response, mechanisms of treatment failure, and an overall viable option for investigating novel therapeutic modalities [141,142].”
BackgroundEstablishment of advanced tumor organoids with emerging innovative technologies
Mao, Y., & Hu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217122 · Cited by 20
Vitacolonna, M., Bruch, R., Agaçi, A., Nürnberg, E., Cesetti, T., Keller, F., Padovani, F., Sauer, S., Schmoller, K. M., Reischl, M., et al. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1422235 · Cited by 18
“Organoids, with their higher degree of differentiation and tissue-like organization, often exhibit drug responses that are more predictive of in vivo outcomes compared to spheroids (Vlachogiannis et al., 2018; LeBlanc et al., 2021).”
BackgroundSENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration
Shao, Z., Liu, S., Sun, W., Zhuang, X., Yin, S., Cheng, J., Xia, X., Liao, Y., Liu, J., & Huang, H. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00665-8 · Cited by 16
Chai, X., Tao, Q., & Li, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146901 · Cited by 23
“Patient-derived tumor chips accurately predict clinical treatment responses, improving outcomes for cancers such as glioblastoma and colorectal carcinoma [217,218].”
Korch, C. T., & Varella‐Garcia, M. (2018) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2018.07.003 · Cited by 19
Mauri, G., Durinikova, E., Amatu, A., Tosi, F., Cassingena, A., Rizzetto, F., Buzo, K., Arcella, P., Aquilano, M. C., Bonoldi, E., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00143 · Cited by 23
Marinucci, M., Ercan, C., Taha‐Mehlitz, S., Fourie, L., Panebianco, F., Bianco, G., Gallon, J., Staubli, S. M., Soysal, S. D., Zettl, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.781833 · Cited by 19
“Indeed, PDOs have been shown to recapitulate the cellular heterogeneity of the primary tissue and can be maintained long term while retaining genetic stability (7).”
BackgroundTROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer
Liu, X., Zhou, T., Wang, Y., Pei, M., Wang, G., Chu, W., Wang, Q., Du, S., Wang, H., & Wang, C. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s354048 · Cited by 17
Johnson, P. A., Menegatti, S., Chambers, A. C., Alibhai, D., Collard, T. J., Williams, A. C., Bayley, H., & Perriman, A. W. (2023) · Biofabrication · doi:10.1088/1758-5090/ac999f · Cited by 16
Hoarau-Véchot, J., Blot-Dupin, M., Pauly, L., Touboul, C., Rafii, S., Rafii, A., & Pasquier, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214173 · Cited by 16
Mirza, S., Bhadresha, K. P., Jameel, M., McCabe, M., Shahbazi, R., Ruff, P., & Penny, C. B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023565 · Cited by 18
Linares, J., Varese, M., Sallent-Aragay, A., Méndez-Vicente, A., Palomo‐Ponce, S., Iglesias, M., Batlle, E., Pisonero, J., Montagut, C. O., Giralt, E., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01717 · Cited by 17
Önder, C. E., Ziegler, T. J., Becker, R., Brucker, S. Y., Hartkopf, A. D., Engler, T., & Koch, A. (2023) · Cancers · doi:10.3390/cancers15143602 · Cited by 21
“Organoids of different sources have already been utilized in various methods including drug development and the determination of drug response [23].”
Method
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.